2018 American Transplant Congress
Contemporary Desensitization with Low Dose Rituximab Ensures Kidney Transplant Outcome beyond ABO Blood Type Incompatibility:A Comparison between past Regimens in Single Institute
Kidney Transplant Surgery and Urology, Sapporo City General Hospital, Sapporo, Japan.
INTRODUCTION: An ABO incompatible kidney transplant (ABOiKT) requires desensitization (DS). The ways of DS have been changed chronologically and the outcome could have been subsequently…2018 American Transplant Congress
Experience with Alemtuzumab Induction with Tacrolimus/Mycophenolate +/- Steroids in Simultaneous Pancreas-Kidney Transplant Recipients with Portal-Enteric Drainage
Surgery, Medicine, Pathology, Pharmacy, Wake Forest Baptist Medical Center, Winston-Salem, NC.
Introduction: Simultaneous pancreas-kidney transplant (SPKT) recipients are a relatively homogeneous population that are considered high immunological risk because of younger age, presumed autoimmune etiology of…2018 American Transplant Congress
Lack of Efficacy of Eculizumab for Prevention of Delayed Graft Function (DGF) in Deceased Donor Kidney Transplant Recipients
DGF portends poor short- and long-term renal function, increases cost, and may reduce graft survival. We studied the safety/efficacy of eculizumab (ECU), a C5 convertase…2018 American Transplant Congress
Digital Health Education for the Pediatric Solid Organ Transplant Population
Background: Self-management and adherence are key factors that influence post transplant graft survival. Education after solid organ transplant plays an important role in providing patients…2018 American Transplant Congress
Early Steroid Withdrawal or Tacrolimus Minimization versus Standard Immunosuppression in Renal Transplant Recipients: The Allegro Trial
BackgroundCurrent immunosuppressive regimen in most renal transplant recipients (RTR) combines basiliximab induction with tacrolimus, mycophenolic acid and prednisolone maintenance therapy. Reduction of immunosuppression by withdrawal…2018 American Transplant Congress
Comparison of Low Dose and Very Low Dose Extended-Release Tacrolimus / MMF in De Novo Kidney Transplant Recipients- 3 Years Follow-Up
Recently, once-daily tacrolimus extended-release formulation (TACER) has been accepted in kidney transplantation, however its optimal dosing are not well evaluated. We have validated low dose…2018 American Transplant Congress
Treatment of BK Viremia: Single-Center Experience
Nephrology, University of Kentucky, Lexington, KY.
INTRODUCTION:BK viremia (BKV) and BK virus nephropathy (BKVN) is recognized as an emerging problem in renal transplant recipients. Only reduction of immunosuppressants had shown efficacy…2018 American Transplant Congress
Exploring Immunosuppressant Medication Adherence in Kidney Transplant Recipients
Imperial College Renal and Transplant Centre, London, United Kingdom.
IntroductionNonadherence to immunosuppressive medication is associated with poor outcomes following kidney transplantation. The aim of this study was to describe the beliefs, understanding and experience…2018 American Transplant Congress
Association of Immunosuppressive Therapy Regimen with Sepsis Outcomes among Kidney Transplant Recipients
OBJECTIVE: Immunosuppressive therapy (IST) could impact sepsis outcomes by altering the host immune response. We examined the associations of IST regimens with sepsis outcomes among…2018 American Transplant Congress
Human Thrombomodulin Expression on Genetically Modified Donor Pigs is Required to Maintain the Anti-Coagulation Profile
Introduction: Coagulation dysregulation is major limitation for xenotransplantation but it is resolved to some extent by making genetically engineered (GE) pigs, which express complement inhibitors…
- « Previous Page
- 1
- …
- 73
- 74
- 75
- 76
- 77
- …
- 138
- Next Page »